FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-028								
- 1		la constant								

37 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or s	section	on 30(n)	of the II	nvestmei	nt Coi	mpany Act	01 19	40							
Name and Address of Reporting Person*  White Marris I.					2. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [ APVO ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
White Marvin L					zapro zmerupeuneo mer [ m v o ]									X Dire		ctor 10% (		Owner		
(Last) (First) (Middle)						Date of Earliest Transaction (Month/Day/Year)									X Office below				r (specify v)	
					06/14/2019										President and CEO					
2401 4TH AVENUE																				
SUITE 1050													_							
(Street)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
SEATTLE WA 98121														X Form filed by One Reporting Person						
														Form filed by More than One Reporting Person						
(City)	(St	ate) (	Zip)													1 013	O11			
		Tabl	e I - Non	-Deriva	ative	Se	curitie	s Acc	quired,	Dis	posed o	f, o	r Ben	efici	ally (	Owne	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		Disposed	ities Acquired (A) d Of (D) (Instr. 3, 4			4 and Se Be Ov		ount of ties cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount		(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)			(11150.4)	
Common Stock 06/14/.					/2019						50,000	0	A	\$0.8	8(1)	8(1) 293,603		D		
		Та	ıble II - D (e								osed of, onvertib				y Ov	vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date if any (Month/Day/Yea	Date,	Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		e	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3			9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code		(A)		Date Exercisa		Expiration Date	Title	or Nui of	ount nber ıres						

#### **Explanation of Responses:**

1. The purchase price of \$0.88 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from \$0.85 to \$0.88. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

### Remarks:

06/14/2019 /s/ White, Marvin L

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.